Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C Virus Infection
Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients
enrolled participants were treated orally with SOF plus a fixed dose combination of OBV/PTV/r plus RBV.
- Trial name
- NCT04391985
- Testing
- SOF plus (OBV/PTV/r) plus RBV
- Where
- Egypt
- Volunteers
- 113 people
- Sponsor
- Beni-Suef University
Hepatitis C
Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir plus ribavirin administered for 16 weeks and 24 weeks in participants with chronic genotype 1 (GT1) or genotype 3 (GT3) hepatitis C virus…
- Trial name
- NCT01896193
- Testing
- SOF, RBV
- Where
- 16 sites in Russia
- Volunteers
- 127 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects
The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of HEC74647 combined with HEC110114 in healthy subjects
- Trial name
- NCT04232514
- Testing
- HEC74647, HEC110114
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
HCV, HCC
the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths in the world.
- Trial name
- ZEPATIER (NCT03110055)
- Testing
- Grazoprevir/Elbasvir, Medical records, Transarterial Chemoembolization
- Volunteers
- 20 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Chronic Hepatitis C
Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection
Phase I/II trial of KRN7000 in patients with chronic hepatitis C. Study objectives: To evaluate and compare the safety and tolerability of 3 ascending doses of a-GalCer.
- Trial name
- NCT00352235
- Testing
- KRN7000
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Foundation for Liver Research
Chronic Hepatitis C
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight.
- Trial name
- NCT01464008
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis C
Retrieval of Hepatitis C Patients Lost to Follow-up
The main purpose of the study is to compare the efficacy of two strategies aimed to rescue patients lost to follow-up with active infection or with positive HCV antibodies without RNA request to complete evaluation and…
- Trial name
- NCT04153708
- Testing
- Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call., Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter
- Where
- Spain
- Volunteers
- 352 people
- Sponsor
- University of La Laguna
Drug Use Disorders, Hepatitis C
Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3
The goal of this study was to effectively use a client-centered community-based intervention to engage people who inject drugs (PWIDs) in healthcare that helps reduce risky behaviors and lower infectious disease risks.
- Conditions
- Drug Use Disorders, Hepatitis C, Harm Reduction, Opioid-use Disorder
- Trial name
- NCT04268173
- Testing
- Community-Based, Client-Centered Prevention Home
- Where
- 6 sites in United States
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Chronic Hepatitis C
"Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt
The primary purpose of the ANRS 12332 HepNile study cohort is to assess in "Real-Life" condition the efficacy and the safety profile of new Direct Acting Antivirals (DAAs) introduced in the Egyptian National Treatment Programme…
- Trial name
- HepNile (NCT03510637)
- Where
- 3 sites in Egypt
- Volunteers
- 7,500 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
This is a three-year (except for participants with chronic kidney disease [CKD] or cirrhosis) multicenter study to follow participants who received at least one dose of grazoprevir (MK-5172) in a previous study to determine…
- Trial name
- NCT01667081
- Testing
- Grazoprevir
- Volunteers
- 2,438 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Response Guided Treatment With Direct Acting Anti-Viral Medications for Chronic HCV Infection
To evaluate the efficacy and safety of direct acting anti-viral agents (DAA) therapy in chronically infected Hepatitis C Virus (HCV) patients using an individualized response guided therapy (RGT) model.
- Trial name
- NCT03603327
- Testing
- Direct acting anti-viral agents
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Soroka University Medical Center
Hepatitis C, Liver Cirrhoses
Simplified Monitoring Myanmar SM2 Study
The study will evaluate the proportion of patients with undetectable HCV RNA at 12 weeks post-treatment (SVR12) following a course of DAA therapy delivered using a simplified schedule of safety and virological monitoring.
- Conditions
- Hepatitis C, Liver Cirrhoses, Liver Inflammation, HIV Infections
- Trial name
- SM2 (NCT04113629)
- Testing
- HCV point of care machine
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Kirby Institute
HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
- Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
- Trial name
- NCT07037277
- Testing
- Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir
- Where
- 107 sites in Egypt, France and 15 more
- Volunteers
- 880 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis C, Substance Use Disorders
HCV Treatment in a Low-threshold Clinic
This is a cohort of people who inject drugs with chronic HCV infection. Patients are seen at a low-threshold clinic. All patients are offered treatment for HCV and subsequently followed for to years
- Trial name
- Prindsen (NCT04063839)
- Testing
- Elbasvir / Grazoprevir Oral Tablet
- Where
- Norway
- Volunteers
- 300 people
- Sponsor
- University Hospital, Akershus
Hepatitis C, Chronic
Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.
GSK2878175 is a site IV NS5B non-nucleoside inhibitor (NNI) being developed for the treatment of chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT02014571
- Testing
- GSK2878175
- Where
- Puerto Rico
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic, HIV Infection
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
The main objective is to evaluate the hepatic safety of raltegravir when compared to efavirenz, both in combination with tenofovir and emtricitabine as first-line HIV treatment in patients with HIV and hepatitis C coinfection.
- Trial name
- NCT01147107
- Testing
- Raltegravir, Efavirenz
- Where
- 2 sites in Vietnam
- Volunteers
- 80 people
- Sponsor
- University of Hawaii
HCV Infection
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of escalating multiple doses of the ABT-333 tablet formulation in healthy adult subjects.
- Trial name
- NCT00909636
- Testing
- ABT-333
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Abbott
Hepatitis C Virus Infection
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis
The purpose of the study is to evaluate the efficacy and safety of a treatment regimen of 12 weeks or 8 weeks of simeprevir in combination with sofosbuvir in chronic hepatitis C virus (HCV) genotype 1 infected men and women…
- Trial name
- NCT02114177
- Testing
- Simeprevir, Sofosbuvir
- Where
- 40 sites in United States, Canada
- Volunteers
- 310 people
- Sponsor
- Janssen Infectious Diseases BVBA
Hepatitis D, Hepatitis C
Evaluation of Patients With Liver Disease
The proposed study aims to evaluate, investigate, and follow-up patients suffering from acute and chronic liver disease. The study will focus on understanding diseases affecting the liver.
- Conditions
- Hepatitis D, Hepatitis C, Hepatitis B, Liver Disease
- Trial name
- NCT00001971
- Where
- United States
- Volunteers
- 8,050 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Viral Hepatitis C
Re-linkage to Care of Patients With Hepatitis C
The purpose of this study is to identify patients with chronic hepatitis C virus (HCV) who were lost of follow up and relinkage them to hepatitis C care
- Trial name
- NCT04470271
- Testing
- Patients with hepatitis C lost follow up
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- Austral University, Argentina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.